NGLFINE Stock Overview
Manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for NGLFINE from our risk checks.
NGL Fine-Chem Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,064.45 |
| 52 Week High | ₹2,823.90 |
| 52 Week Low | ₹1,728.10 |
| Beta | 1.05 |
| 11 Month Change | -2.81% |
| 3 Month Change | -18.67% |
| 1 Year Change | 10.24% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 10.46% |
Recent News & Updates
Recent updates
NGL Fine-Chem's (NSE:NGLFINE) Promising Earnings May Rest On Soft Foundations
May 28
NGL Fine-Chem Limited's (NSE:NGLFINE) 26% Price Boost Is Out Of Tune With Earnings
Apr 20NGL Fine-Chem Limited (NSE:NGLFINE) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Nov 18Weak Statutory Earnings May Not Tell The Whole Story For NGL Fine-Chem (NSE:NGLFINE)
Nov 05Shareholder Returns
| NGLFINE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.9% | -0.8% | -0.9% |
| 1Y | 10.2% | 60.3% | 39.7% |
Return vs Industry: NGLFINE underperformed the Indian Pharmaceuticals industry which returned 60.3% over the past year.
Return vs Market: NGLFINE underperformed the Indian Market which returned 39.7% over the past year.
Price Volatility
| NGLFINE volatility | |
|---|---|
| NGLFINE Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.4% |
| 10% least volatile stocks in IN Market | 3.9% |
Stable Share Price: NGLFINE has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: NGLFINE's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 682 | Rahul Nachane | www.nglfinechem.com |
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. The company offers animal health pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine hcl, s-methoprene, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, carprofen, fenbendazole, and xylazine hydrochloride. It also offers human health pharmaceutical ingredients comprising of nitazoxanide and atovaquone; and intermediates and specialty chemicals consisting of trimethyl, triazacylononane, and ethyl glucamine.
NGL Fine-Chem Limited Fundamentals Summary
| NGLFINE fundamental statistics | |
|---|---|
| Market cap | ₹12.74b |
| Earnings (TTM) | ₹420.29m |
| Revenue (TTM) | ₹3.58b |
30.3x
P/E Ratio3.6x
P/S RatioIs NGLFINE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGLFINE income statement (TTM) | |
|---|---|
| Revenue | ₹3.58b |
| Cost of Revenue | ₹1.82b |
| Gross Profit | ₹1.76b |
| Other Expenses | ₹1.34b |
| Earnings | ₹420.29m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 68.03 |
| Gross Margin | 49.13% |
| Net Profit Margin | 11.73% |
| Debt/Equity Ratio | 12.9% |
How did NGLFINE perform over the long term?
See historical performance and comparison